Compare Crispr Therapeutics AG (CRSP) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Jabil Inc — how do they compare? Crispr Therapeutics AG trades at $53.04 (market cap $4.88B), while Jabil Inc trades at $299.39 (market cap $31.35B). The key difference: Jabil Inc is far larger — about 6.4× Crispr Therapeutics AG's market cap, and Jabil Inc pays a 0.11% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Jabil Inc for 23 Days on average.
| CRSP | JBL | |
|---|---|---|
Market Cap | $4.88B | $31.35B |
Volume | 2,861,747 | 1,337,978 |
Sector | Health | Technology |
52-Week High | $74.92 | $385.50 |
52-Week Low | $44.34 | $192.49 |
Typical Hold Time | 77 Days | 23 Days |
Enterprise Value | $3.30B | $33.63B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
JBL trades at $299.47, down 3.14% amid bearish technical signals despite strong Q4 2026 earnings that beat estimates with EPS of $4.40 versus $4.07 expected. The stock shows neutral oscillators but bearish moving averages, with support at $296 and resistance at $303. Revenue grew to $29.80B in 2025 with net income of $657M, while 2026 projections indicate $36.0B revenue and $1.0B net income, supported by AI infrastructure demand.
Outlook remains positive with 60.87% analyst buy ratings and a $434.75 consensus price target implying 45% upside. Key risks include high debt levels and market volatility, but strong earnings momentum and AI-driven growth in fiscal 2027 provide investment opportunity. Monitor execution against guidance and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
